

**UnitedHealthcare Community Plan Pharmacy & Therapeutics Committee Minutes**

Meeting Date: June 17, 2021

Location: Via conference call/Teams

Agenda Item	Speaker	Recommendation	Conclusions/Recommendations	Vote
Meeting called to order	G. Shutzberg	5:03 PM		
<b>A. Minutes of previous meetings</b>	G. Shutzberg	<b>Review of Minutes from March 18, 2021</b>	Minutes reviewed, approved	Yes
<b>B. Formulary Review - New Drugs</b>	G. Shutzberg	<b>Imcivree</b> Recommendation: • Benefit Exclusion across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:00
	G. Shutzberg	<b>Zokinvy</b> Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:00
	G. Shutzberg	<b>Gemtesa</b> Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:00
	G. Shutzberg	<b>Klisyri</b> Recommendation: • Non-preferred with prior authorization across all applicable lines of business Comment: Discussion was held regarding the pricing of the Fluorouracil 0.5% cream.	Motion made, seconded, and carried to accept recommendation	10:00
	G. Shutzberg	<b>Orgovyx</b> Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:00
	M. Reisman	<b>Bronchitol</b> Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:00
	M. Reisman	<b>Lupkynis</b> Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:00
	M. Reisman	<b>Tepmetko</b> Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:00
	M. Reisman	<b>Ukoniq</b> Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:00
	M. Reisman	<b>Verquvo</b> Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:00
<b>B. Formulary Review - Class Reviews</b>	G. Shutzberg	<b>Hereditary Angioedema (HAE): Orladeyo</b> Confirm class review	Yes/No	Yes
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:00
	M. Reisman	<b>Growth Hormones: Sogroya</b> Confirm class review	Yes/No	Yes
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:00
	G. Shutzberg	<b>Integrase Inhibitors: Cabenuva and Vocabria</b> Confirm class review	Yes/No	Yes
		Recommendation: • Vocabria - Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:00
		Recommendation: • Cabenuva - Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:00

Agenda Item	Speaker	Recommendation	Conclusions/Recommendations	Vote
<b>B. Formulary Review - New Formulations</b>	G. Shutzberg	<b>Confirm Review of New Formulations Grid</b>	Yes/No	Yes
		<b>Wynzora</b>		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:00
<b>B. Formulary Review - PDL Modifications</b>	M. Reisman	<b>Confirm Review of PDL Modifications Grid</b>	Yes/No	Yes
		Recommendation: • <b>Clobetasol 0.05% cream and ointment:</b> Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:00
		Recommendation: • <b>Fenofibrate 145mg tablet:</b> Move to preferred with step therapy across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:00
		Recommendation: • <b>Fluocinonide 0.1% cream:</b> Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:00
		Recommendation: • <b>Fluoxetine 40mg capsule:</b> Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:00
		Recommendation: • <b>Naproxen Sodium 125mg/ 5mL suspension:</b> Move to preferred with age edit across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:00
	Comment:	Discussion was held regarding the age edit on the Naproxen sodium 125mg/5ml suspension. Requesting to increase the maximum age edit to 10 years and above. UHC Clinical Pharmacy team to review.		
<b>B. Formulary Review - New Drugs- Medical</b>	M. Reisman	<b>Confirm Review of New Drugs- Medical Grid</b>	Yes/No	Yes
		<b>Oxlumo</b>		
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:00
		<b>Danyelza</b>		
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:00
		<b>Breyanzi</b>		
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:00
		<b>Ziextenzo</b>		
		Recommendation: • Medical Benefit; Preferred with prior authorization required across all applicable lines of business • Pharmacy Benefit; Preferred with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:00
<b>B. Formulary Review - Drugs Evaluated Per Grid</b>	G. Shutzberg	<b>Apply recommendations as outlined in grid</b>	Motion made, seconded, and carried to accept recommendation	10:0
<b>C. Clinical Guidelines</b>	G. Shutzberg	<b>Clinical Guideline Review</b>		
		<b>Apply New Pharmacy Guidelines</b>	Motion made, seconded, and carried to accept recommendation	10:00
		<b>Continue to Apply Pharmacy Guidelines Requiring Modifications</b>	Motion made, seconded, and carried to accept recommendation	10:00
		<b>Remove Pharmacy Guidelines Requiring Archival</b>	Motion made, seconded, and carried to accept recommendation	10:00

Agenda Item	Speaker	Recommendation	Conclusions/Recommendations	Vote
<b>D. Quality Monitoring</b>	S. Kulik/G. Shutzberg	<b>Confirm Review of Quality Data</b>	Yes/No	Yes
	S. Kulik	DUR Review		
	Comment:	<ul style="list-style-type: none"> <li>• Discussion was held regarding the dosing requirements of fluoxetine and risperidone and the pediatric population.</li> <li>• Discussion was held regarding the dosing of Seroquel for the pediatric population who have a diagnosis of insomnia.</li> </ul>		
	G. Shutzberg	Top 25 Drugs by Cost and Volume – 1st Quarter 2021		
	G. Shutzberg	Top 10 Drugs Requested - Approvals and Denials – 1st Quarter 2021		
	G. Shutzberg	Grievances and Appeals Data – 1st Quarter 2021		
	G. Shutzberg	Inter-Rater Reliability (IRR) – 1st Quarter 2021		
		• Pharmacists		
<b>Adjournment</b>	G. Shutzberg		6:40 PM	
Comments: <ul style="list-style-type: none"> <li>• Carl Tepper documented on his tally that the DUR was excellent.</li> <li>• Dr. Jeff Williams documented on his tally that he supports the age edit to be set at 10 years of age for naproxen 125 mg/5ml suspension.</li> <li>• Dr. Pappalardo documented on his tally that the age edit cut off of 10 years for naproxen suspension seems a bit low. Specifically if a patient has development delays.</li> </ul>				

Respectfully Submitted to the Committee,

James P. Hancovsky, M.S.I.A., R.Ph.  
Chief Pharmacy Officer, UHC C&S